Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03190278 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia, sponsored by Cellectis S.A..
- Active
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 8
- Study locations
NCT03190278 is a Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia that is active but no longer recruiting, run by Cellectis S.A.. The registered enrollment target is 29 participants. The trial reports 8 study locations across 7 states.
The verdict
NCT03190278, a Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Cellectis S.A..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 8
- Study locations
Study Summary
Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of Universal Chimeric Antigen Receptor T-cells targeting CD123 (UCART123v1.2) and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Conditions Studied
Interventions
- BIOLOGICAL UCART123v1.2
Study Locations (8)
New York
- Roswell Park Cancer Institute - Buffalo
- Weill Medical College of Cornell University - New York
California
- University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center - San Francisco
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- University of Pennsylvania - Abramson Cancer Center - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-06-19 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03190278
The ClinicalTrials.gov registry entry for NCT03190278 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellectis S.A., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which UCART123v1.2 is the first listed.
NCT03190278 reports 8 study locations spanning 7 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03190278 about?
NCT03190278 is a clinical study titled "Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is ...
What is the current status of trial NCT03190278?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2017-06-19. Estimated completion is 2025-12.
What conditions does trial NCT03190278 study?
This clinical trial studies the following conditions: Relapsed/Refractory Acute Myeloid Leukemia.
What interventions are being tested in trial NCT03190278?
The interventions under investigation include: UCART123v1.2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03190278?
This trial is sponsored by Cellectis S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03190278 being conducted?
This trial has 8 study locations across California, Florida, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.